1型糖尿病青少年的睡眠教练干预:理由和试验设计
Sarah S Jaser1, Jill Simmons1, Lauren L Milner1
1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Contemporary clinical trials
|September 12, 2025
概括
一种针对1型糖尿病 (T1D) 青少年的新型睡眠辅导干预可以改善睡眠时间和血糖控制. 这种方法旨在加强糖尿病管理,减少年轻人的健康并发症风险.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 行为科学 行为科学
- 睡眠医学 睡眠医学
背景情况:
- 大多数患有1型糖尿病 (T1D) 的青少年无法达到血糖目标,增加并发症风险.
- 睡眠不足会对胰岛素敏感性和执行功能产生负面影响,阻碍T1D管理.
- 需要新的干预措施来改善青少年糖尿病护理.
研究的目的:
- 评估T1D青少年的促进睡眠的行为干预 (睡眠教练).
- 评估干预对睡眠时间,可变性,执行功能和血糖结果的影响.
- 为了确定个性化睡眠指导是否可以改善糖尿病管理.
主要方法:
- 随机对照试验与150名青少年 (11-17岁) 患有T1D.
- 干预组接受了睡眠指导;对照组接受了增强的常规护理.
- 主要结果 (睡眠时间/时间) 和次要结果 (执行功能,血糖控制) 在12个月内进行评估.
主要成果:
- 据假设,睡眠教练组中的青少年的睡眠持续时间显著增加,睡眠变化减少.
- 预计这项干预措施将对执行功能和血糖控制 (血红蛋白A1c,时间范围) 产生积极影响.
结论:
- 睡眠教练的干预显示了改善T1D青少年认知和血糖结果的潜力.
- 这种远程可交付的行为干预可以广泛传播.
- 改善睡眠可能是改善青少年糖尿病管理的关键因素.
更多相关视频
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Insulin: Dosing Regimen and Adverse Effects
695
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
695
Diabetes: Management and Pharmacotherapy
870
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
870


